Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
DMart, Trent, HUL among top UBS picks as brokerage bets on consumer sector rebound in FY26
22/04/2025
Tariff uncertainty and rising localization costs could further squeeze IT margins : Sandip Agarwal
22/04/2025
Falling credit cost to help Yes Bank achieve 1% ROA in next two financial years : Prashant Kumar
22/04/2025
Metal stocks surge up to 3% as India imposes 12% safeguard duty on steel imports for 200 days
22/04/2025
Q4 results today : HCL Tech, Waaree Energies among 16 companies to announce earnings on Tuesday
22/04/2025
Dollar wallows near 3-year low as Trump's attacks on Fed chief unnerve traders
22/04/2025
